KLOW 80MG is a specialised four-component research blend containing GHK-Cu 50mg, BPC-157 10mg, TB-500 10mg and KPV 10mg.
Designed for qualified laboratory and analytical investigation involving peptide characteristics, molecular pathways, cellular signalling and multi-component experimental models.
For Research Use Only – Not for human or veterinary consumption.
$162.41
KLOW 80MG is a specialised four-component peptide blend developed for controlled laboratory, biochemical and analytical research. The formulation combines GHK-Cu, BPC-157, TB-500 and KPV in one research preparation, giving qualified researchers a convenient material for investigating multiple peptide-associated pathways within appropriately designed experimental models.
The standard 80MG formulation contains:
Each component has attracted scientific interest independently, particularly in research involving cellular signalling, extracellular matrix biology, inflammatory pathways, peptide interactions and related molecular processes.
KLOW 80MG from Axion Peptide Lab is supplied exclusively as a scientific research material.
For Research Use Only – Not for human consumption.
KLOW is not one individual peptide molecule. Instead, it is a multi-component preparation containing four distinct peptide materials.
The largest component is GHK-Cu, a naturally occurring copper-binding tripeptide complex consisting of glycine, histidine and lysine associated with copper. It has been extensively investigated in experimental research concerning extracellular matrix biology, cellular processes and copper-dependent molecular mechanisms.
BPC-157 is a synthetic 15-amino-acid peptide studied primarily in preclinical experimental models.
TB-500 is associated with thymosin beta-4-related peptide research and has attracted interest in investigations involving actin-associated processes and cellular migration.
KPV is the tripeptide sequence lysine-proline-valine and is associated with alpha-melanocyte-stimulating hormone-related research.
Combining these four materials creates a distinctive preparation for appropriately controlled multi-peptide experiments.
The KLOW formulation provides researchers with four structurally different materials in a fixed research format.
GHK-Cu has been investigated in areas involving copper transport, extracellular matrix processes and cellular signalling.
BPC-157 appears primarily within preclinical research involving cellular, vascular and tissue-associated experimental models.
TB-500 and thymosin-related peptides have been investigated in areas involving cellular migration and actin-associated biological processes.
KPV has attracted experimental interest involving inflammatory signalling and epithelial research models.
These research areas relate primarily to investigations of the individual components.
Scientists should not assume that combining the four materials automatically produces the same experimental observations reported when each component is investigated independently.
Multi-component preparations offer interesting possibilities for experimental research.
Biological systems frequently involve numerous signalling pathways operating simultaneously. Researchers may therefore want to observe how different molecular materials behave when introduced into the same controlled experimental environment.
KLOW provides a fixed preparation that can support this type of exploratory investigation.
Potential areas include peptide interaction studies, molecular pathway analysis, comparative experiments, cellular signalling investigations and analytical characterisation.
However, the convenience of a blend also creates an important experimental limitation.
If an observation occurs while researchers are using the complete formulation, determining which individual component contributed to that observation can be difficult.
Researchers requiring precise control over individual components may therefore prefer separate materials.
KLOW 80MG may be incorporated into appropriately designed analytical workflows where scientists are investigating peptide characteristics.
Research objectives may involve:
The appropriate methodology depends entirely on the objectives of the laboratory.
Researchers should establish suitable controls, analytical equipment, concentrations, environmental conditions and acceptance criteria before beginning experiments.
The 80MG designation refers to the combined quantity of research material within the formulation.
In the commonly listed composition, GHK-Cu accounts for 50mg while BPC-157, TB-500 and KPV each account for 10mg.
This creates a total material quantity of 80mg.
The designation should not be interpreted as a recommended human dosage.
Axion Peptide Lab does not provide personal dosing schedules, administration instructions, injection protocols or therapeutic recommendations for KLOW or other laboratory peptides.
The material is intended exclusively for appropriately controlled scientific investigation.
Consistency is an important consideration when conducting peptide experiments.
Changes in material identity, purity, storage conditions, contamination or handling can introduce additional variables into laboratory investigations.
Researchers should therefore evaluate product specifications and available batch documentation before incorporating any material into sensitive experimental workflows.
Using a pre-formulated multi-component preparation can also provide consistency between experiments where researchers specifically require the same fixed combination.
Scientists should document relevant product and batch information as part of their normal laboratory procedures.
Peptide materials require appropriate laboratory handling.
Environmental factors including temperature, moisture, light exposure, contamination and repeated environmental fluctuations may affect research-material stability.
Researchers should follow the product-specific storage information supplied with their particular batch.
Laboratories should also maintain clear identification throughout the material’s lifecycle.
KLOW should remain separated from food, pharmaceuticals, supplements and consumer products.
Only appropriately trained laboratory personnel should handle experimental peptide materials, with suitable personal protective equipment and institutional safety procedures used where applicable.
Axion Peptide Lab focuses on specialised peptide materials intended exclusively for scientific and analytical investigation.
Our goal is to provide researchers with clearly identified materials suitable for carefully controlled experimental workflows.
Researchers choosing Axion Peptide Lab can expect an emphasis on:
Documentation and analytical information may vary between products and batches. Researchers requiring specific testing information should verify the documentation available for their chosen batch before ordering.
Qualified researchers, analytical laboratories, scientific organisations, biotechnology facilities and institutions can source KLOW 80MG through Axion Peptide Lab for legitimate research applications.
Before ordering, customers should confirm that this fixed four-component formulation is appropriate for their experimental objectives.
Researchers are responsible for ensuring that acquisition, possession, importation and laboratory use comply with applicable regulations within their jurisdiction.
Product availability and delivery eligibility may vary according to destination.
For specific questions concerning batch specifications or available analytical documentation, contact Axion Peptide Lab before ordering.
KLOW 80MG is supplied strictly as laboratory research material.
It is not a pharmaceutical product, dietary supplement, food, cosmetic or consumer healthcare product.
The information presented here describes scientific research contexts and should not be interpreted as medical advice or evidence that KLOW can diagnose, treat, cure, mitigate or prevent any disease, injury or medical condition.
No human dosage, administration or therapeutic recommendations are provided.
For Research Use Only – Not for human or veterinary consumption.
KLOW 80MG is a multi-component laboratory preparation combining GHK-Cu, BPC-157, TB-500 and KPV in one research format.
The commonly used formulation contains GHK-Cu 50mg, BPC-157 10mg, TB-500 10mg and KPV 10mg, providing 80mg of total material.
No. KLOW is a blend of four separate peptide materials rather than one individual peptide molecule.
GHK-Cu is a copper-binding tripeptide complex that has been investigated in experimental research involving extracellular matrix biology, copper-associated mechanisms and cellular processes.
KPV is the tripeptide lysine-proline-valine. It has been investigated experimentally in areas including inflammatory signalling and epithelial biology.
The components have individual research literature, but findings concerning individual materials should not automatically be attributed to the four-component blend. KLOW is supplied for laboratory research rather than clinical use.
No. Axion Peptide Lab supplies KLOW strictly as a laboratory research material. It is not intended for human or veterinary consumption or administration.
No. The 80MG designation represents the combined quantity of material supplied and is not a human dosage recommendation.
Researchers should follow the storage requirements provided with their specific product and batch while protecting laboratory materials from inappropriate environmental conditions.
Qualified research customers can order KLOW 80MG through AxionPeptideLab.com, subject to product availability, destination eligibility and applicable regulations.
